Pinealon vs Semax — both Russian-developed, very different evidence bases
Semax is a synthetic analogue of a fragment of adrenocorticotropic hormone, with the larger published footprint of the two including clinical work conducted in Russia. Pinealon is a three-amino-acid bioregulator from the Russian peptide-bioregulator programme, with a much smaller and predominantly preclinical literature. They share a country of origin and nothing structural.
These get sold together and discussed as siblings. They are not related molecules, and the difference in how much is actually known about each is larger than most comparisons admit.
Origins and evidence
| Semax | Pinealon | |
|---|---|---|
| Derived from | A fragment of adrenocorticotropic hormone | Russian peptide-bioregulator programme |
| Length | Seven amino acids | Three amino acids |
| Published footprint | Larger, includes Russian clinical work | Smaller, predominantly preclinical |
| Independent replication | Limited outside the originating environment | Limited |
Asymmetric evidence is worth naming
A comparison that treats both sides as equally supported misrepresents the situation. One has clinical work behind it, whatever the caveats about where it was conducted. The other does not. That asymmetry is the most useful thing this comparison can tell you.
- Check whether a cited study is accessible, not merely cited.
- Distinguish preclinical from clinical work — routinely conflated for both.
- Note when every claim traces to the same research group.
- Treat a translated abstract as an abstract, not a methods section.
The compounds discussed here
Go deeper
Frequently asked questions
- Are Pinealon and Semax related?
- Only by development origin. Semax derives from an ACTH fragment; Pinealon is a tripeptide from the bioregulator programme that also produced Epitalon and Cartalax. They are unrelated molecules.
- Which has more research behind it?
- Semax, clearly. Its literature includes clinical work conducted in Russia. Pinealon's is smaller and largely preclinical, concentrated within one research tradition.
- Why is the research hard to check?
- Much of it is published in Russian-language journals, some not indexed in the databases most readers search. Claims circulate widely while the underlying papers are rarely read.
References
Primary literature for the compounds above. Links open the record on PubMed.
- The efficacy of semax in the treatment of patients at different stages of ischemic stroke Gusev EI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID 29798983 → · summary
- Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex Stavchansky VV, et al. Bull Exp Biol Med. 2007. PMID 17603664 → · summary